News & Updates
Excerpt from the Press Release: REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of irreversible small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, announced today that BMF-219 displayed remarkable…
Excerpt from the Press Release: REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) — Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that the first patient has…
Excerpt from the Press Release: – 33% Objective Response Rate (ORR) was observed in 33 RECIST evaluable patients across all FolRα expression levels and both dose levels. – Dose response was observed, with a 47% ORR in 17 patients who started at the 5.2 mg/kg dose level. – Tumor proportion score (TPS) was selected as…
New agreement paves the way for better mouse models to study how the human immune system fights SARS-CoV-2 Excerpt from the Press Release: LA JOLLA, CA—Scientists at La Jolla Institute for Immunology (LJI) and Charles River Laboratories International, Inc., are launching a new project to uncover exactly how different cells in the human immune system…
Immunology portfolio highlighted by success of a second positive study with AVTX-002 further validates the LIGHT mechanism of action in inflammatory diseases Efficacy signal demonstrated in heavily pre-treated subjects support further evaluation in inflammatory bowel disease patients’ refractory to three or more treatments, including anti-TNF alpha and other biologics Expands AVTX-002 target indications to include…
AC5® Advanced Wound System demonstrated notable improvement in healing after only 3 to 6 applications—with only weekly clinic visits and reapplication Excerpt from the Press Release: FRAMINGHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices,…
First patient randomized in pivotal phase III study evaluating radiotherapy-activated NBTXR3 with or without cetuximab in high-risk elderly patients with locally advanced head and neck squamous cell carcinoma The randomized study is designed to demonstrate treatment outcome superiority of radiotherapy-activated NBTXR3 versus the standard of care for global registration The US Food and Drug Administration…
Excerpt from the Press Release: The Wistar Institute announces the initiation of a Phase 2 clinical study of VK-2019 in patients with advanced Epstein-Barr Virus (EBV)-positive nasopharyngeal carcinoma (NPC) and lymphoma. The study, led by researchers at the Stanford University School of Medicine, will enroll patients who have recurred or progressed following standard therapy or have…
Excerpt from the Press Release: PLEASANTON, Calif., Jan. 5, 2022 /PRNewswire/ — DiaCarta Inc., a precision molecular diagnostics company and leading developer of novel oncology tests using liquid biopsy today announced that the company, under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health, will collaborate on…
Excerpt from the Press Release: By Celine Zadorsky Sepsis is a life-threatening condition that occurs when the body’s response to an infection triggers excessive inflammation. The inflammatory response can cause damage to organs such as the heart, liver, lungs and brain. While there are currently limited treatments for sepsis, researchers at Lawson Health Research Institute…
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?